The biotech company said Friday the latest version of its Covid-19 mRNA vaccine, Spikevax, has been authorized by Health Canada. And for the first time, all pre-filled syringe doses of the vaccine ...

The payoff in lives and hospital time saved runs at about 100 to 1 per dollar invested, which is a great deal by any standard ...

New data from the Kentucky Cabinet for Health and Family Services shows cases of the virus have jumped significantly in the ...

Since COVID, there've been growing initiatives in Africa to start producing vaccines and medicines locally, thus gaining greater independence from global supply chains. But are these schemes ...

BioNTech SE is currently sponsoring a Phase II clinical study titled A Phase II, Multisite, Open-label, Single Arm Trial of BNT327 in Combination With Docetaxel in Second-line Stage IV Non-small Cell ...

The NHS has announced that it will fast-track patients with advanced head and neck cancers in England into a clinical trial ...

The intervention being tested is BNT323/DB-1303, an investigational drug administered via intravenous infusion. It is being compared against standard chemotherapy drugs, doxorubicin or paclitaxel, ...

BioNTech (BNTX) recently experienced a 10% price increase in the last quarter, coinciding with the Health Canada's authorization of its variant-adapted COMIRNATY COVID-19 vaccine, a potential positive ...

Released Tuesday, the AAP's recommendations call for routine vaccination of children ages 6 months to 2 years, citing ...

Multiple scientists and doctors have spoken out against this decision, including infectious diseases expert Dr. Thomas A. Russo, who told Newsweek that mRNA vaccines "will be critical when the next, ...

Texas school districts are coming back from summer with a rising number of parents asking for vaccine exemption forms and a ...

Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...